-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GY4WgafEgYgcGrEoNuYit0gCoWsJH1Kfre2RCVHCMRIzfKtkervgLQx4v3QjMWxU zNnY6frV3P3QFLk6WyUxow== 0000950162-04-000148.txt : 20040211 0000950162-04-000148.hdr.sgml : 20040211 20040211153037 ACCESSION NUMBER: 0000950162-04-000148 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20040211 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ELAN INTERNATIONAL SERVICES LTD CENTRAL INDEX KEY: 0001002782 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 102 JAMES COURT FLATTS STREET 2: SMITH PARISH FL 04 CITY: BERMUDA STATE: D0 ZIP: 00000 BUSINESS PHONE: 4412929169 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: DOV PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001066833 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223374365 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-78237 FILM NUMBER: 04586168 BUSINESS ADDRESS: STREET 1: 433 HACKENSACK AVENUE CITY: HACKENSACK STATE: NJ ZIP: 07601 BUSINESS PHONE: 2019680980 MAIL ADDRESS: STREET 1: 433 HACKENSACK AVENUE CITY: HACKENSACK STATE: NJ ZIP: 07601 SC 13G/A 1 dov-elan13dano1021104.txt AMENDMENT NO. 1 SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A1 Under the Securities Exchange Act of 1934 (Amendment No. 1)* DOV Pharmaceutical, Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, par value $.0001 per Share - -------------------------------------------------------------------------------- (Title of Class of Securities) 259858108 - -------------------------------------------------------------------------------- (CUSIP Number) December 31, 2003 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: / / Rule 13d-1(b) / / Rule 13d-1(c) /X/ Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP 259858108 SCHEDULE 13G -2- - -------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Elan Corporation, plc - -------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) / / (b) / / - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization Ireland - -------------------------------------------------------------------------------- 5. Sole Voting Power 0 ----------------------------------------------------- Number of 6. Shared Voting Power Shares Beneficially 4,150,511 ----------------------------------------------------- Owned by Each 7. Sole Dispositive Power Reporting Person With: 0 ----------------------------------------------------- 8. Shared Dispositive Power 4,150,511 - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 4,150,511 - -------------------------------------------------------------------------------- 10. Check box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) / / - -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row (9) 20.7% - -------------------------------------------------------------------------------- 12. Type of Reporting Person (See Instructions) CO CUSIP 259858108 SCHEDULE 13G -3- - -------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Elan International Services, Ltd. - -------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) / / (b) / / - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization Bermuda - -------------------------------------------------------------------------------- 5. Sole Voting Power 0 ----------------------------------------------------- Number of 6. Shared Voting Power Shares Beneficially 4,150,511 ----------------------------------------------------- Owned by Each 7. Sole Dispositive Power Reporting Person With: 0 ----------------------------------------------------- 8. Shared Dispositive Power 4,150,511 - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 4,150,511 - -------------------------------------------------------------------------------- 10. Check box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) / / - -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row (9) 20.7% - -------------------------------------------------------------------------------- 12. Type of Reporting Person (See Instructions) CO CUSIP 259858108 SCHEDULE 13G -4- - -------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Elan Pharmaceutical Investments, Ltd. - -------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) / / (b) / / - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization Bermuda - -------------------------------------------------------------------------------- 5. Sole Voting Power 0 ----------------------------------------------------- Number of 6. Shared Voting Power Shares Beneficially 1,221,046 ----------------------------------------------------- Owned by Each 7. Sole Dispositive Power Reporting Person With: 0 ----------------------------------------------------- 8. Shared Dispositive Power 1,221,046 - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,221,046 - -------------------------------------------------------------------------------- 10. Check box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) / / - -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row (9) 7.1% - -------------------------------------------------------------------------------- 12. Type of Reporting Person (See Instructions) CO CUSIP 259858108 SCHEDULE 13G -5- Item 1(a). Name of Issuer: DOV Pharmaceutical, Inc. Item 1(b). Address of Issuer's Principal Executive Offices: 433 Hackensack Avenue, Hackensack, New Jersey 07601 Item 2(a). Name of Person Filing: This statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons") (i) Elan Corporation, plc (ii) Elan International Services, Ltd. (iii) Elan Pharmaceutical Investments, Ltd. Item 2(b). Address of Principal Business Office: (i) Elan Corporation, plc Lincoln House, Lincoln Place Dublin 2, Ireland (ii) Elan International Services, Ltd. 102 St. James Court Flatts, Smiths FL 04 Bermuda (iii) Elan Pharmaceutical Investments, Ltd. 102 St. James Court Flatts, Smiths FL 04 Bermuda Item 2(c). Citizenship: (i) Elan Corporation, plc is an Irish public limited company (ii) Elan International Services, Ltd. is a Bermuda exempted limited liability company (iii) Elan Pharmaceutical Investments, Ltd. is a Bermuda exempted limited liability company Item 2(d). Title of Class of Securities: Common Stock, par value $.0001 per share (the "Shares") Item 2(e). CUSIP Number: 259858108 Item 3. If this statement is filed pursuant to ss.ss.240.13d-1(b) or 240.13d-2(b) or (c), check whether the person is a: This Item 3 is not applicable CUSIP 259858108 SCHEDULE 13G -6- Item 4. Ownership: Elan Corporation plc
(a) Amount beneficially owned as of February 11, 2004: 4,150,511 (1) (b) Percent of class: 20.7% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 0 (ii) shared power to vote or to direct the vote: 4,150,511 (1) (iii) sole power to dispose or to direct the disposition of: 0 (iv) shared power to dispose or to direct the disposition of: 4,150,511 (1) Elan International Services, Ltd. (a) Amount beneficially owned as of February 11, 2004: 4,150,511 (1) (b) Percent of class: 20.7% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 0 (ii) shared power to vote or to direct the vote: 4,150,511 (1) (iii) sole power to dispose or to direct the disposition of: 0 (iv) shared power to dispose or to direct the disposition of: 4,150,511 (1) Elan Pharmaceutical Investments, Ltd. (a) Amount beneficially owned as of February 11, 2004: 1,221,046 (1) (b) Percent of class: 7.1% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 0 (ii) shared power to vote or to direct the vote: 1,221,046 (1) (iii) sole power to dispose or to direct the disposition of: 0 (iv) shared power to dispose or to direct the disposition of: 1,221,046 (1)
CUSIP 259858108 SCHEDULE 13G -7- - ---------- (1) 2,929,465 of the shares are beneficially owned directly by Elan International Services, Ltd., a direct wholly-owned subsidiary of Elan Corporation, plc, and 1,221,046 of the shares are beneficially owned directly by Elan Pharmaceutical Investments Ltd., a direct wholly-owned subsidiary of Elan International Services, Ltd. CUSIP 259858108 SCHEDULE 13G -8- Item 5. Ownership of Five Percent or Less of a Class: Not Applicable Item 6. Ownership of More than Five Percent on Behalf of Another Person: Not Applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person: Not Applicable Item 8. Identification and Classification of Members of the Group: Not Applicable Item 9. Notice of Dissolution of Group: Not Applicable Item 10. Certifications: Not Applicable. CUSIP 259858108 SCHEDULE 13G -9- SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 11, 2004 ELAN CORPORATION, PLC By: /s/ William F. Daniel ----------------------------------- Name: William F. Daniel Title: Executive Vice President and Secretary Dated: February 11, 2004 ELAN INTERNATIONAL SERVICES, LTD. By: /s/ Kevin Insley ----------------------------------- Name: Kevin Insley Title: President and Chief Financial Officer Dated: February 11, 2004 ELAN PHARMACEUTICAL INVESTMENTS, LTD. By: /s/ Kevin Insley ----------------------------------- Name: Kevin Insley Title: President and Chief Financial Officer CUSIP 259858108 SCHEDULE 13G -10- EXHIBIT INDEX Page No. A. Joint Filing Agreement dated February 11, 2004 by and among Elan Corporation, plc, Elan International Services, Ltd. and Elan Pharmaceutical Investments, Ltd........................ .....................................11 CUSIP 259858108 SCHEDULE 13G -11- EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of DOV Pharmaceutical, Inc., dated as of February 11, 2004 is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934. Dated: February 11, 2004 ELAN CORPORATION, PLC By: /s/ William F. Daniel ----------------------------------- Name: William F. Daniel Title: Executive Vice President and Secretary Dated: February 11, 2004 ELAN INTERNATIONAL SERVICES, LTD. By: /s/ Kevin Insley ----------------------------------- Name: Kevin Insley Title: President and Chief Financial Officer Dated: February 11, 2004 ELAN PHARMACEUTICAL INVESTMENTS, LTD. By: /s/ Kevin Insley ----------------------------------- Name: Kevin Insley Title: President and Chief Financial Officer -----END PRIVACY-ENHANCED MESSAGE-----